A pilot study investigating the in vitro efficacy of sucralfate against common veterinary cutaneous pathogens
| Autor: | M. J. Boord, J. M. Blondeau, R. Ghubash, T. Yen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Veterinary medicine
Staphylococcus pseudintermedius 040301 veterinary sciences Sucralfate Pilot Projects Microbial Sensitivity Tests medicine.disease_cause Enterococcus faecalis 0403 veterinary science 030207 dermatology & venereal diseases 03 medical and health sciences Minimum inhibitory concentration 0302 clinical medicine medicine Animals Small Animals biology Bacteria Pseudomonas aeruginosa business.industry 04 agricultural and veterinary sciences biology.organism_classification Antimicrobial Proteus mirabilis Anti-Bacterial Agents Pyoderma Staphylococcus aureus business medicine.drug |
| Zdroj: | The Journal of small animal practice. 59(11) |
| ISSN: | 1748-5827 |
| Popis: | OBJECTIVE To determine whether Cicalfate® (Avene), a commercially available skin cream, or its active ingredient - sucralfate - demonstrate in vitro antimicrobial effect against common veterinary cutaneous pathogens. MATERIALS AND METHODS Prospective study assessing in vitro susceptibility of standardised and clinical strains of common veterinary cutaneous pathogens to titrated concentrations of sucralfate in either saline solution (range 0∙2 to 200 mg/mL) or in Cicalfate® restorative cream solubilised in DMSO (range 0∙002 to 1 mg/mL). Minimum inhibitory concentrations were determined by broth dilution in accordance with Clinical and Laboratory Standards Institute guidelines. RESULTS Both solutions demonstrated in vitro inhibitory effects against strains of Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus pseudintermedius, Escherichia coli and Enterococcus faecalis. Minimum inhibitory concentration ranges for susceptible bacteria tested in Cicalfate® solution and sucralfate solution were 0∙06 to 0∙25 mg/mL and 25 to 50 mg/mL, respectively. Sucralfate solution did not demonstrate antimicrobial effects against laboratory strains of S. aureus and E. faecalis and neither solution demonstrated antimicrobial effects against the clinical strain of P. aeruginosa. For organisms inhibited by sucralfate, Cicalfate® solution inhibited growth at lower sucralfate concentrations than sucralfate solution. CLINICAL SIGNIFICANCE The results of this pilot study suggest that Cicalfate® and sucralfate demonstrate in vitro antibacterial activity. Further in vitro and clinical studies are warranted to confirm these observations and determine their clinical utility in the treatment of superficial pyoderma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text